7850.Two

The company's capital structure is characterized by a high proportion of equity, with total equity of 850,658,000 TWD and total liabilities of 57,459,000 TWD, resulting in a debt-to-equity ratio of 0.04. The liquidity position is marked by a current ratio of 30.8, indicating strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag.

Profitability metrics show a significant challenge, with a return on equity of -10.25% and a return on assets of -9.6%. These figures are well below the industry norms for a biotechnology and medical research firm, indicating poor performance in generating returns from equity and assets. The company reported a net loss of 87,204,000 TWD and an operating loss of 116,966,000 TWD, further highlighting the financial distress.

The company's revenue is concentrated in a single segment, as no specific segments are disclosed, and there is no geographic breakdown provided. This lack of diversification could pose a risk if the primary market experiences a downturn. The company's revenue of 68,000,000 TWD is modest, and the operating cash flow is negative at -95,952,000 TWD, indicating that the company is not generating sufficient cash from operations to sustain its activities.

The growth trajectory is negative, with the company reporting a net loss and negative operating and free cash flows. The outlook for the current fiscal year is not provided, but the historical performance suggests a continued decline in profitability. The capital expenditure of -9,388,000 TWD indicates that the company is not investing in new projects or infrastructure, which could hinder future growth.

The risk assessment highlights a medium liquidity risk due to the negative net cash position after subtracting total debt. The dilution risk is low, as there is no indication of potential share dilution. The company has not made any recent public filings or transcripts that would suggest significant changes in its business strategy or financial position.

Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's financial performance remains a concern, with no clear signs of improvement in the near term. The lack of positive cash flow and the continued losses suggest that the company may need to seek additional financing or restructuring to remain viable.